IL6 and ovarian carcinoma: A phase II study suggested that the extent of IL-6 increase in the plasma during treatment was associated with an inferior outcome in patients with rectal and ovarian cancer after bevacizumab and chemoradiation treatment, and an inferior outcome in patients with advanced HCC after sunitinib therapy [46, 47].